ABSK-112
- Generic Name
- ABSK-112
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Abbisko Therapeutics Co, Ltd
- Target Recruit Count
- 164
- Registration Number
- NCT06225804
- Locations
- 🇨🇳
The first Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Harbin, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Jilin Cancer Hospital, Changchun, Jilin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath